Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Export

@article{citeulike:1586101, abstract = {BACKGROUND: GABAergic medications appear to reduce the reinforcing effects of cocaine by attenuating cocaine-induced dopamine release. This study evaluated gabapentin and tiagabine compared to placebo in reducing cocaine taking behavior. METHODS: A total of 76 treatment seeking, cocaine dependent, methadone-treated, predominately Caucasian male subjects were randomly assigned to tiagabine 24 mg/day (N=25), gabapentin 2400 mg/day (N=26) or placebo (N=25) in a 10-week double-blind placebo-controlled trial. Study medications were slowly increased to their full dosages by the end of week 5 and maintained through week 10. The primary outcome measure was thrice-weekly drug free urine samples. RESULTS: Treatment retention was significantly less for the gabapentin group relative to the other groups (log rank=5.29, d.f.=1, p=0.02). The proportion of cocaine-free urine samples during weeks 6-10 was significantly larger in the tiagabine treated group (p<0.05). The longitudinal data showed significant change in thrice-weekly cocaine free urines that reached a greater abstinent rate for the tiagabine treated group (22\%) compared to gabapentin (5\%) or placebo (13\%) treated groups. Mixed-effects ordinal regression models showed a significant tiagabine by time interaction compared to gabapentin (Z=2.48, d.f.=1, p=0.01) and placebo (Z=3.90, d.f.=1, p=0.0001). The gabapentin group did not differ from placebo. CONCLUSION: Gabapentin showed poor treatment retention and ineffectiveness in reducing cocaine use. Tiagabine significantly reduced cocaine taking behavior compared to placebo or gabapentin among methadone-stabilized cocaine abusers.}, address = {Department of Psychiatry, Yale University, New Haven, CT 06511, USA. gerardo.gonzalez-haddad@yale.edu}, author = {Gonz\'{a}lez, Gerardo and Desai, Rani and Sofuoglu, Mehmet and Poling, Jim and Oliveto, Alison and Gonsai, Kishor and Kosten, Thomas R.}, citeulike-article-id = {1586101}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.drugalcdep.2006.07.003}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/16930857}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=16930857}, citeulike-linkout-3 = {http://www.sciencedirect.com/science/article/B6T63-4KPP48G-F/2/2d9c9cc6513b2d435cbc01b5db8088a6}, day = {23}, doi = {10.1016/j.drugalcdep.2006.07.003}, issn = {0376-8716}, journal = {Drug and alcohol dependence}, keywords = {cocaine, gabapentin, methadone, tiagabine}, month = {February}, number = {1}, pages = {1--9}, posted-at = {2009-09-10 21:32:22}, priority = {2}, title = {Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients.}, url = {http://dx.doi.org/10.1016/j.drugalcdep.2006.07.003}, volume = {87}, year = {2007} }

TY - JOUR ID - citeulike:1586101 L3 - citeulike-article-id:1586101 N2 - BACKGROUND: GABAergic medications appear to reduce the reinforcing effects of cocaine by attenuating cocaine-induced dopamine release. This study evaluated gabapentin and tiagabine compared to placebo in reducing cocaine taking behavior. METHODS: A total of 76 treatment seeking, cocaine dependent, methadone-treated, predominately Caucasian male subjects were randomly assigned to tiagabine 24 mg/day (N=25), gabapentin 2400 mg/day (N=26) or placebo (N=25) in a 10-week double-blind placebo-controlled trial. Study medications were slowly increased to their full dosages by the end of week 5 and maintained through week 10. The primary outcome measure was thrice-weekly drug free urine samples. RESULTS: Treatment retention was significantly less for the gabapentin group relative to the other groups (log rank=5.29, d.f.=1, p=0.02). The proportion of cocaine-free urine samples during weeks 6-10 was significantly larger in the tiagabine treated group (p<0.05). The longitudinal data showed significant change in thrice-weekly cocaine free urines that reached a greater abstinent rate for the tiagabine treated group (22%) compared to gabapentin (5%) or placebo (13%) treated groups. Mixed-effects ordinal regression models showed a significant tiagabine by time interaction compared to gabapentin (Z=2.48, d.f.=1, p=0.01) and placebo (Z=3.90, d.f.=1, p=0.0001). The gabapentin group did not differ from placebo. CONCLUSION: Gabapentin showed poor treatment retention and ineffectiveness in reducing cocaine use. Tiagabine significantly reduced cocaine taking behavior compared to placebo or gabapentin among methadone-stabilized cocaine abusers. IS - 1 JF - Drug and alcohol dependence SN - 0376-8716 AD - Department of Psychiatry, Yale University, New Haven, CT 06511, USA. gerardo.gonzalez-haddad@yale.edu EP - 9 TI - Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. VL - 87 SP - 1 KW - cocaine KW - gabapentin KW - methadone KW - tiagabine AU - González, Gerardo AU - Desai, Rani AU - Sofuoglu, Mehmet AU - Poling, Jim AU - Oliveto, Alison AU - Gonsai, Kishor AU - Kosten, Thomas PY - 2007/02/23/ UR - http://dx.doi.org/10.1016/j.drugalcdep.2006.07.003 ER -